The two most common elements in the universe are Hydrogen and stupidity.”
- Harlan Ellison
Today, we look at a 'Tier 4' biotech concern trying an unusual route to target rare and orphan diseases. A full investment analysis is provided in the paragraphs below.
Company Overview
Akari Therapeutics (AKTX) is a United States-based clinical-stage biotech company that is dedicated to discovering and developing inhibitors of acute and chronic inflammation of the complement and leukotriene system for the treatment of rare and orphan diseases with high unmet need. Conceptually, Akari believes